A summary of research written by Vibeke Strand, MD, clinical professor in division of immunology/rheumatology at Stanford University School of Medicine, gave an overview of patient-reported outcomes (PROs) in the VOLTAIRE-RA trial.
A summary of research written by Vibeke Strand, MD, clinical professor in division of immunology/rheumatology at Stanford University School of Medicine, gave an overview of patient-reported outcomes (PROs) in the VOLTAIRE-RA trial.
The trial found similar efficacy and safety of the adalimumab biosimilar Cyltezo (adalimumab-adbm; Boehringer Ingelheim) and the reference product (Humira) in patients with moderate to severe rheumatoid arthritis (RA). “Similar substantial benefits across a range of patient-reported outcomes” were reported in VOLTAIRE-RA participants randomized to the biosimilar and originator, Strand wrote.
Adalimumab is a monoclonal antibody targeting tumor necrosis factor-α that has been approved in the US since 2002 and Europe since 2003, and adalimumab-adbm was the first biosimilar adalimumab product approved as interchangeable with the reference product by the FDA.
The summary explained that participants who received the biosimilar had similar symptom reduction and side effects as those who received the reference product and then switched to the biosimilar. Participants were randomized to the biosimilar or reference product for the first 24 weeks, at which point half of the patients on the reference product were randomized to switch to the biosimilar. PROs were recorded at 12 and 24 weeks after the start of treatment to assess whether there were differences in the effects of biosimilar and reference product treatment on health-related quality of life.
Participants in the study completed a 36-item questionnaire (SF-36) to assess patient-reported health status across eight domains: physical functioning, physical role limitations, bodily pain, general health perceptions, energy/vitality, social functioning, emotional role limitations, and mental health. These outcomes are evaluated individually and grouped into the physical component summary score and mental component summary score. Patients also completed surveys assessing their perception of their disease activity and health-related quality of life.
At 12 and 24 weeks, the 2 treatment groups showed similar improvements in both physical and mental component summary scores. Mental component scores improved by 70% in the reference product group and 68% in the biosimilar group, physical component score by 59% and 56%, levels of improvement considered clinically important. There were no significant differences in physical component summary scores between groups at baseline, week 12, or week 24. Mental component summary scores were somewhat higher in the reference product group at baseline, but improvements at weeks 12 and 24 were similar between groups.
Improvements across all domains showed no significant differences between groups. Regarding individual domains, the author explained that more than two-thirds of participants reported clinically meaningful improvements in domains such as physical functioning, bodily pain, and vitality, and more than half reported improvements in others such as general health, emotional role limitations, and social functioning.
According to the summary, the VOLTAIRE-RA trial found people with rheumatoid arthritis receiving either the biosimilar adalimumab-adbm or the reference product experienced similar improvements in symptoms and similar levels of side effects, and these effects “translated into highly similar clinically meaningful improvements in experience and perception.” The author added that “a high proportion” of participants in the trial reported greater improvements compared to a reference US population similar in age and sex, and this finding “represents attainment of a treatment goal that was difficult to achieve in early trials of non-biologic treatments for rheumatoid arthritis.”
Reference
Strand V. Summary of research: effects of adalimumab-adbm versus adalimumab reference product on patient-reported outcomes in rheumatoid arthritis: results from VOLTAIRE-RA. Rheumatol Ther. Published online August 9, 2024. doi: 10.1007/s40744-024-00691-0
Breaking Barriers in Osteoporosis Care: New Denosumab Biosimilars Wyost, Jubbonti Approved
June 16th 2024In this episode, The Center for Biosimilars® delves into the FDA approval of the first denosumab biosimilars, Wyost and Jubbonti (denosumab-bbdz), and discuss their potential to revolutionize osteoporosis treatment with expert insights from 2 rheumatologists.
Eye on Pharma: EC Approved Ustekinumab; Zymfentra Expansion; Biosimilar Policy Briefing
September 26th 2024The European Commission (EC) approved Celltrion's ustekinumab biosimilar for chronic inflammatory diseases, Celltrion expanded access to Zymfentra (subcutaneous infliximab-dyyb) through partnerships with Cigna and Express Scripts, and the Association for Accessible Medicines held a policy briefing addressing barriers to biosimilar adoption.
Biosimilars Gastroenterology Roundup for May 2024—Podcast Edition
June 2nd 2024On this episode of Not So Different, we review the biggest gastroenterology biosimilar stories from May 2024, covering new data from conferences and journals on infliximab and adalimumab products that demonstrate positive clinical results and confirm the safety of these biosimilars, as well as the feasibility of switching to them.
Expanding Biosimilar Adoption: Insights and Strategies With Dr Sophia Humphreys
September 16th 2024Sophia Humphreys, PharmD, MHA, BCBBS, director of system formulary management at Sutter Health, discusses the challenges of expanding biosimilars into new therapeutic areas and highlights the role of education, competitive pricing, and integrated delivery networks in improving adoption and market growth.